Endocrine Abstracts

Introduction: Corticosteroid-induced diabetes (CID) is a common and potentially harmful problem in clinical practice. Its pathophysiological mechanisms are multiple, from increased hepatic neoglucogenesis to peripheral insulin resistance or direct toxic effect on the β cell. The aim of our study was to study the clinical profile of patients who developed corticosteroid-induced diabetes and its factors of occurrence.

Method: We report a retrospective study conducted from January 2017, on the patients followed in consultation of Endocrinology - Diabetology of Ibn Rochd University Hospital of Casablanca. Every diabetes discovered after long-term corticosteroid therapy (>3 months) was considered as cortico-induced diabetes. The studied parameters were: age, sex, BMI, family history of diabetes, duration and dose of corticosteroid therapy, treatment adopted. The statistical analysis was unified using SPSS software version 22.0.0.

Results: Our study focused on 36 patients who developed CID, with an average age of 58±4.7 years, a female predominance with a F/H ratio of 1.7. The average BMI was 28.5±5.8 kg/m². Family history of Diabetes was found in 56% of cases. Glucocorticoid was orally in the majority of cases with an average dose of 30 mg/day. The average duration of onset of CID was 2.8 years, with an HbA1c average of 6.8%. The risk factors significantly associated with the development of CID were: high age (>65 years) (P=0.03), duration of corticosteroid therapy (P=0.012), BMI (P=0.005), diabetic heredity (P=0.02) and elevated HbA1c (P=0.01). The dose of corticosteroid therapy was frequently associated with no significant result (P=0.67).

Discussion: Corticosteroids-induced diabetes is a common problem, whose risk factors are similar to those of type 2 diabetes, hence the need for rigorous monitoring of patients at risk.